Regenacy Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$17.1M
- Investors
-
7
Regenacy Pharmaceuticals General Information
Description
Developer of therapeutic drugs designed for the treatment of peripheral neuropathy. The company's drugs utilize the regeneration of normal protein function using oral, isoform-selective histone deacetylase enzyme inhibitors to develop selective inhibitors and ricolinostat, enabling physicians to treat sickle cell disease and beta-thalassemia.
Contact Information
Website
www.regenacy.comCorporate Office
- 303 Wyman Street
- Suite 300
- Waltham, MA 02451
- United States
Corporate Office
- 303 Wyman Street
- Suite 300
- Waltham, MA 02451
- United States
Regenacy Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 24-Aug-2022 | $17.1M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series A) | 19-Mar-2020 | Completed | Clinical Trials - Phase 2 | |||
| 1. Angel (individual) | Completed | Startup |
Regenacy Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Regenacy Pharmaceuticals Comparisons
Industry
Financing
Details
Regenacy Pharmaceuticals Competitors (22)
One of Regenacy Pharmaceuticals’s 22 competitors is Harmony Biosciences, a Formerly VC-backed company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Harmony Biosciences | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| BiOrion | Venture Capital-Backed | Groningen, Netherlands | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland |
Regenacy Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Regenacy Pharmaceuticals Patents
Regenacy Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3113819-A1 | Pyrimidine and pyrazine hdac1,2 inhibitors | Pending | 10-Oct-2018 | ||
| EP-3863631-A1 | Pyrimidine and pyrazine hdac1,2 inhibitors | Inactive | 10-Oct-2018 | ||
| EP-3863631-A4 | Pyrimidine and pyrazine hdac1,2 inhibitors | Inactive | 10-Oct-2018 | ||
| US-20210332036-A1 | Pyrimidine and pyrazine hdac1,2 inhibitors | Inactive | 10-Oct-2018 | ||
| CA-3112330-A1 | Hdac1,2 inhibitors | Pending | 25-Sep-2018 | C07D409/12 |
Regenacy Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Regenacy Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3E Bioventures (China) | Venture Capital | Minority | ||
| Cobro Ventures | Venture Capital | Minority | ||
| Rivas Capital | Venture Capital | Minority | ||
| Taiwania Capital | Venture Capital | Minority | ||
| TA YA VENTURE HOLDINGS LIMITED | Venture Capital | Minority |
Regenacy Pharmaceuticals Investments (1)
Regenacy Pharmaceuticals’s most recent deal was a Joint Venture with BC Regenacy. The deal was made on 14-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BC Regenacy | 14-Jul-2020 | Joint Venture | Drug Discovery |
Regenacy Pharmaceuticals FAQs
-
When was Regenacy Pharmaceuticals founded?
Regenacy Pharmaceuticals was founded in 2016.
-
Where is Regenacy Pharmaceuticals headquartered?
Regenacy Pharmaceuticals is headquartered in Waltham, MA.
-
What is the size of Regenacy Pharmaceuticals?
Regenacy Pharmaceuticals has 6 total employees.
-
What industry is Regenacy Pharmaceuticals in?
Regenacy Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Regenacy Pharmaceuticals a private or public company?
Regenacy Pharmaceuticals is a Private company.
-
What is the current valuation of Regenacy Pharmaceuticals?
The current valuation of Regenacy Pharmaceuticals is .
-
What is Regenacy Pharmaceuticals’s current revenue?
The current revenue for Regenacy Pharmaceuticals is .
-
How much funding has Regenacy Pharmaceuticals raised over time?
Regenacy Pharmaceuticals has raised $47.1M.
-
Who are Regenacy Pharmaceuticals’s investors?
3E Bioventures (China), Cobro Ventures, Rivas Capital, Taiwania Capital, and TA YA VENTURE HOLDINGS LIMITED are 5 of 7 investors who have invested in Regenacy Pharmaceuticals.
-
Who are Regenacy Pharmaceuticals’s competitors?
Harmony Biosciences, Ability Pharma, Alnylam Pharmaceuticals, BiOrion, and Virometix are some of the 22 competitors of Regenacy Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
